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Influenza A virus production
Process intensification
Semi-perfusion
Cell culture-based vaccine manufacturinga b s t r a c t
Control and prevention of rapid influenza spread among humans depend on the availability of efficient
and safe seasonal and pandemic vaccines, made primarily from inactivated influenza virus particles.
Current influenza virus production processes rely heavily on embryonated chicken eggs or on cell culture
as substrate for virus propagation. Today’s efforts towards process intensification in animal cell culture
could innovate viral vaccine manufacturing using high-yield suspension cells in high cell density perfu-
sion processes. In this work, we present a MDCK cell line adapted to grow as single cell suspension with a
doubling time of less than 20 h, achieving cell concentrations over 1  107 cells/mL in batch mode.
Influenza A virus titer obtained in batch infections were 3.6 log10(HAU/100 mL) for total- and 109 viri-
ons/mL for infectious virus particles (TCID50), respectively. In semi-perfusion mode concentrations up
to 6  107 cells/mL, accumulated virus titer of 4.5 log10(HAU/100 mL) and infectious titer of almost
1010 virions/mL (TCID50) were possible. This exceeds results reported previously for cell culture-based
influenza virus propagation by far and suggests perfusion cultures as the preferred method in viral
vaccine manufacturing.
 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Influenza virus infections are responsible for millions of flu
patients and associated with 290,000–650,000 annual deaths
worldwide [1]. Additionally, outbreaks of pandemic influenza virus
strains have caused millions of deaths in the last century, and still
are a threat for the future [2]. To minimize influenza spread, limit
health risks and reduce its economic burden, vaccination cam-
paigns pose a huge demand with 500 million vaccine doses to be
manufactured and distributed each year (2015) [3,4]. Besides tradi-
tional egg-based vaccine manufacturing, production platforms
based on cell culture contribute increasingly to an overall growing
market. In contrast to eggs, animal cells can be propagated in
chemically defined media lacking potential allergens, are indepen-
dent from egg supply chains, enable fast scale-up and large scale
manufacturing with a relatively small foot print [5,6]. For influenza
vaccine manufacturing, animal cells are either used for recombi-
nant expression of viral antigens or as a host cell substrate forthe propagation of whole virions [7,8]. The first recombinant influ-
enza vaccine (Flublok) was commercialized in 2014, using insect
cells for the expression of hemagglutinin (HA) antigens [9,10]. For
viral human influenza vaccines, only the mammalian Vero and
Madin-Darby canine kidney (MDCK) cells have been used commer-
cially (Influvac, Optaflu/Flucelvax, Preflucel) [7,11]. Addition-
ally, HEK293 and other cell lines like Per.C6, EB66, CAP, AGE1.
CR were evaluated as a cell substrate for influenza virus propaga-
tion [11–14]. High specific growth rates, high cell concentrations
and growth in single cell suspension in chemically defined media
make these cell lines very interesting for influenza virus produc-
tion. However, with a cell-specific virus yield (CSVY) exceeding
10,000 virions/cell (5  104 HAU/cell), MDCK cells remain the
most productive cell line for influenza viruses [15]. Initially, MDCK
cells were cultivated as adherent cells on microcarriers [16–19].
Further cell line and media development led to MDCK suspension
cell lines, used both in academia [20–23] and industry [24]. These
cell lines, however, typically have a lower specific growth rate,
grow only to rather low cell densities and/or as cell aggregates or
display lower specific virus yields. Only recently, advances in med-
ium development led to fast growing MDCK suspension cells
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and medium development, process intensification towards high
cell density (HCD) perfusion culture can increase virus titers or
overall process productivity [27,28]. Perfusion technologies are
already applied successfully to intensify CHO cell-based manufac-
turing of recombinant proteins [29]. More recently, this technology
was also evaluated in more detail for cell culture-based virus prop-
agation [30–33]. Finding the best perfusion strategy for both cell
growth and virus propagation phase is needed, to prevent medium
limitations and maintain cell-specific productivity avoiding the so
called ‘‘cell density effect” [34,35]. Depending on specific demands
of the cell line and cultivation media available, the cell specific per-
fusion rate (CSPR) has to be optimized towards optimal cell growth
with minimal medium consumption [36]. To mimic lab-scale per-
fusion processes, shaker experiments in semi-perfusion can be
applied as a scale-down model [27]. First experiments with
HEK293, AGE1.CR and CAP cells showed the potential of influenza
virus production at high cell density. However, low CSVY didn’t
lead to significantly higher virus titers than those obtained with
MDCK cell-based processes [30,31].
In the presented study, we demonstrate the adaptation of a
MDCK suspension cell line to a new cultivation medium (XenoTM),
which enables growth in single cell suspension, high specific
growth rate and high cell concentrations. Additionally to batch
experiments, we evaluate the potential of perfusion cultures for
the manufacturing of influenza virus vaccines. We demonstrate
the possibility to combine the high CSVY of MDCK cells with a high
cell concentration in perfusion systems to maximize influenza
virus titers.2. Material and methods
2.1. Cell lines & cell culture
The MDCK suspension cell line, here referred as MDCK.SUS2
(P43), was previously adapted from adherent MDCK cells (ECACC,
#84121903) to grow in suspension in chemically defined medium
(Smif8 medium, Gibco, acquired through K. Scharfenberg, Univer-
sity of Applied Sciences, Emden/Leer, Germany, supplemented
with 4 mM glutamine, and 4 mM pyruvate) [23]. MDCK.SUS2 cells
adapted to the animal component free medium (XenoTM-S001S,
#FG0100402, Shanghai BioEngine Sci-Tech) were established as a
new cell line, here referred as MDCK.Xeno (see below). Both MDCK
suspension cell lines were cultivated in 50 mL working volume in
shaker flasks (125 mL baffled polycarbonate Erlenmeyer Flask,
Corning, #431405) at 37 C in a 5% CO2 atmosphere with a shak-
ing frequency of 185 rpm (Multitron Pro, Infors HT; 50 mm shaking
throw). Cells were passaged every 3–4 days with seeding cell den-
sity of 0.5  106 cells/mL. Cell concentration, diameter and viabil-
ity were measured with a cell counter (Vi-CELL XR, Beckman
Coulter, #731050), cell concentrations over 10  106 cells/mL were
diluted before measurements with PBS. Due to cell aggregates,
MDCK.SUS2 cells were trypsinized (10 min, 0.9  trypsin, 37 C)
prior to cell counting. Extracellular metabolite concentrations were
measured from the cell free supernatant with a BioProfile 100 Plus
analyzer (Nova Biomedical).2.2. Cell adaptation
For the adaptation of the MDCK.SUS2 (P43) cells to Xeno med-
ium, a step-wise medium change was applied. Over the first adap-
tation period, the content of Xeno medium was increased by 10%
steps. During adaptation, MDCK cells were passaged by spinning
down cells (300g, 5 min, RT) to adjust to 1  106 cells/mL final
inoculation concentration. Cells were resuspended in the newmedium mixture (10% carry over) and cultivated for 3 days. In
cases of low cell growth, additional passages with the same med-
ium mixture were performed to stabilize adaptation.
2.3. Influenza virus infection
All infections were carried out with an influenza A seed virus
strain A/PR/8/34 of the subtype H1N1 (Robert Koch Institute, Ber-
lin, Germany), in the following called influenza A virus or IAV. The
original influenza A virus strain obtained from RKI (Amp. 3138)
was propagated in adherent MDCK cells (ECACC, #84121903).
The infectious titer of the final seed virus was 1.1  109 virions/
mL (TCID50). Trypsin (Gibco, #27250-018; 5000 U/mL in PBS) was
added at time of infection with a final activity of 20–30 U/mL (5–
50  107 U/cell). For infections in semi-perfusion culture, trypsin
was added to the feed at the respective concentration. Immediately
before infection, cells were spun down (300g, 5 min, RT) and 50%
(90% for semi-perfusion) of cell free medium was replaced with
fresh medium.
2.4. Semi-perfusion culture
Semi-perfusion cultures were established to reach high cell den-
sity conditions in shaker flasks [27]. In each perfusion step, cells are
pelleted by centrifugation (400g, 10 min, RT) and up to two third
(33 mL) of the cultivation volume was removed and replaced with
warm, fresh cultivation medium. With increasing cell concentra-
tion, more medium had to be replaced or the time interval between
medium replacements was decreased to realize an overall constant
CSPR. For the calculation of the time of the perfusion step (Eq. (1))
or the perfusion volume (Eq. (2)), a constant specific growth rate of


















Dt: time between perfusion steps (h)
VW: working volume (mL)
[X]: cell concentration (cells/mL)
VP: perfusion volume (mL)
m: specific growth rate (1/h)
CSPR: cell specific perfusion rate (pL/(cell h))
2.5. Hemagglutination assay
In order to quantify the total number of influenza virus parti-
cles, the hemagglutination assay was used as described in detail
by Kalbfuss et al. [37]. Virus containing cell suspension was cen-
trifuged to remove cells and cell debris (2000g, 5 min, RT) and
the supernatant was stored at 80 C until measurement. Virus
samples and HA standard (undiluted and 1:20.5 predilution) were
serially diluted (0.5n with n = 1–12) with PBS in 96 round bottom
wells. 100 mL of chicken erythrocyte solution was added (2  107
erythrocytes/mL) to diluted samples (100 mL) and incubated for
3–8 h at RT. The HA activity was evaluated using a plate reader
(infinite M200 microplate reader, Tecan) measuring the extinc-
tion at 700 nm and the final titer was calculated by a curve fitting
function of the resulting extinction data. The virus titer is
expressed as the common logarithm (log10) of the HA unit (HAU)
per analysis volume (100 mL): log10(HAU/100 mL). The correspond-
ing total number of virus particles was calculated by multiplying
HAU and erythrocyte concentration:




 HAU ¼ 2E7 1
mL
 10log10ðHAU=100lLÞ ð3Þ2.6. TCID50 assay
For the quantification of infectious influenza virus particles the
TCID50 assay was used as described in detail by Genzel and Reichl
[38]. The virus samples were collected from cell culture and spun
down to remove cells and cell debris (2000g, 5 min, RT). Sterile
supernatant was stored until measurement at 80 C. Confluent
MDCK cells in 96 well plates were infected with a serial dilution
of the virus sample and stained after 24 h with an HA specific pri-
mary antibody (anti-influenza A/PR/8/34 H1N1 HA serum,
#03/242, NIBSC) and a fluorescence labeled secondary antibody
(Alexa Fluor donkey anti-sheep IgG antibody, #A11015, Thermo
Fisher Scientific). Fluorescence positive and negative wells were
counted and the infectious virus titer was calculated from eight
replicates according to the Spearman-Kärber method [39,40].
2.7. Accumulated virus titer
The accumulated virus titer (TiterAC) was calculated to allow a
comparison of viral titers in a multiple harvest process (semi-
perfusion) with the batch experiments. For this, the virus titer in
each harvest/perfusion step (titerh) was multiplied by the respec-
tive harvest volume (Vh), summed up and divided by the working





For the calculation of the accumulated HA-titer (HAAC) it has to
be considered that Eq. (4) can only be applied for HA-units (HAU).














A ð5Þ3. Results and discussion
3.1. MDCK.SUS2 adaptation to Xeno medium
The original MDCK.SUS2 cell line cultivated in Smif8 medium
had an average doubling time of 24–26 h (Fig. 1 AI), growing inFig. 1. Adaptation of MDCK.SUS2 cells from Smif8 to Xeno medium (MDCK.Xeno). MDCK.
A: average doubling time (grey bars: ) and average cell diameter ( ) was analyzed o
contrast microscopy pictures of MDCK suspension cells for morphological evaluation in
Xeno).small cell aggregates with variable size (Fig. 1BI). A direct adapta-
tion of this cell line to the Xeno medium failed. Therefore the frac-
tion of Xeno medium was slowly increased or kept constant until
MDCK cells were able to grow in pure Xeno medium with a
promising growth performance. Over the whole adaptation period,
the viability of MDCK cells stayed above 90%. It seemed that the
adaptation had a strong effect on the specific growth rate, but only
minor effect on the overall health of the cell population. The whole
adaptation process was divided into three phases. In the first adap-
tation phase (0–31 days) cell growth was similar or better com-
pared to pure Smif8 cultivations (Fig. 1AII), the size of cell
aggregates increased and a higher maximum cell concentration
was reached (Fig. 1BII). In the second adaptation phase (31–
66 days), cell growth was dramatically decreased with increasing
Xeno content (Fig. 1AIII). Additionally, cellular aggregates disap-
peared and MDCK cells grew as single cells (Fig. 1BIII&IV). After
the second adaptation phase, MDCK cells were growing in pure
Xeno mediumwith a lower doubling time compared to the original
culture (24 vs 34 h). In the third adaptation phase (66–180 days),
cells were cultivated over multiple passages in Xeno medium to
generate the cell line finally selected for process intensification
studies (after 180 days) (Fig. 1AIV). During this adaptation phase,
no morphological changes were observed, but cell metabolism
seemed improved, leading to better specific growth rate, higher
cell concentrations and lower lactate as well as ammonium accu-
mulation. The last adaptation phase could also be considered a
selection phase, where a (sub)population of cells was selected for
more efficient and faster growth. Fully adapted cells (passage 60)
were used to create a cell bank for further experiments. A re-
adaptation of the MDCK.Xeno cell line to Smif8 medium reversed
all the adaptation effects and cells were growing comparable to
the original cell line (data not shown). The long adaptation time
(>50 passages, 180 days) of the MDCK.SUS2 cell line to a stable
MDCK.Xeno cell line with optimal growth in Xeno medium was
rather surprising. In particular, the time period required for cell
adaptation was in a comparable range as establishment of the orig-
inal suspension cell line from adherent MDCK cells (>40 passages)
[23,41]. As both media were developed for suspension cell growth,
we expected a rather fast adaptation of the MDCK.SUS2 cell, but
metabolic and morphological changes, as well as a (sub)population
selection seemed to have increased the adaptation time. We con-
firmed canine origin of the cell line by proteomic analysis (data
not shown), but additional genetic characterization would be nec-
essary for commercial use. Tumorigenicity, which is often a con-
cern for suspension cell lines, should also be tested if commercial
use is anticipated. As other MDCK suspension cells have alreadySUS2 cells were monitored over 60 passages during the adaptation to Xeno medium.
ver the adaptation time and with increasing Xeno medium content ( ). B: Phase
different medium composition (I: 0% Xeno; II: 30% Xeno; III: 60% Xeno; IV: 100%
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presented MDCK.Xeno cell line could be a good candidate for influ-
enza vaccine production [42,43].3.2. Cell growth and metabolism: Smif8 vs Xeno medium
Fully adapted MDCK.Xeno cells were able to grow in Xeno med-
ium to cell concentrations above 13  106 cells/mL in shaker flasks
(Fig. 2D). This was a significant improvement compared to MDCK.
SUS2cells growing in Smif8 medium, where cells usually reach
maximum cell densities between 6 and 8  106 cells/mL (Fig. 2A).
Additionally, MDCK.Xeno cells were able grow with a much higher
specific growth rate (mmax: 0.036 1/h) compared to the MDCK.SUS2
cells (mmax: 0.026 1/h).For both cell lines, the viability (95%) was
stable over the cell growth phase and only decreased after a short
stationary phase together with the viable cell concentration
(Fig. 2A&D). Due to a higher concentration of the main energy
metabolites, glucose and glutamine in the Xeno medium
(Fig. 2B&E), an increase in cell concentrations was not very surpris-
ing. However, in the Xeno medium, single cell MDCK cells could
utilize the available metabolites more efficiently to fuel growth
demands. Interestingly it seemed that higher growth rate of
MDCK.Xeno cells was mainly due to an overall higher consumption
of glucose. Over 96 h of cultivation, the cell-specific consumption
rate of glutamine was quite similar for both cell lines (17 vs 18
fmol/(cell h)), but the consumption rate of glucose was almost
three times higher for MDCK.Xeno cells (26 vs 74 fmol/(cell h))
(Fig. 2C&F). Differences in consumption rates of these primary
energy metabolites were much more visible in the early stage of
cultivation. For MDCK.SUS2 cells, rates of glutamine and glucose
consumption were quite similar over cultivation period of 96 h
(Fig. 2C). For MDCK.Xeno cultivations, however, rates of glutamine
and glucose consumption were highly elevated in the beginning
(0–48 h) and later decreased dramatically (Fig. 2F). This could be
explained partly by a metabolic shift in the middle (72 h) of the
MDCK.Xeno cultivation with a shift from from lactate production
to lactate consumption (Fig. 2E). This effect was not observed forFig. 2. Growth and metabolism of MDCK.SUS2 and MDCK.Xeno cells. MDCK cells were cu
and extracellular metabolites (B & E) were monitored during batch cultivation. Consump
glucose ( );j viable cell concentration, viability, average cell diameter, glutamine
viable cell concentration.MDCK.SUS2 cells, where lactate accumulated to a similar level,
but was not consumed later (Fig. 2B). A higher glutamine concen-
tration in the Xeno medium led to a much higher accumulation of
ammonium of up to 6 mM at 72 h of cultivation (Fig. 2E). For both
cell lines, the cell diameter decreased after 48 h of cultivation. For
the MDCK.Xeno cells there was an additional increase of average
cell diameter during the initial lag phase of the cultivation
(Fig. 2A&D). Here, changes in substrate concentration and decrease
in osmolality (from 320 to 270 mOsm/kg) could have led to varia-
tions in the average cell diameter. Due to their better specific
growth rate, higher maximum cell concentration and single cell
growth, MDCK.Xeno cells easily outperformed not only
MDCK.SUS2 cells, but also other MDCK suspension cell lines
[20–23,26,44]. The only disadvantage was the production of high
amounts of ammonium, which potentially can have a negative
influence on virus replication [45–47].
Overall, these observations demonstrate the impact of medium
development, where without any genetic manipulation massive
changes of cell line performance are possible. Unfortunately, it still
unclear what medium component(s) are linked to the adaptation
to this specific MDCK.Xeno cell phenotype since the medium com-
position is not disclosed and detailed studies regarding uptake and
release of medium compounds and metabolic by-products are still
missing.3.3. Influenza A virus production in batch mode
To evaluate differences between both MDCK suspension cells
with respect to influenza A virus production, each cell line was
inoculated in three shaker flasks with 0.5  106 cells/mL (Xeno)
or 0.8  106 cells/mL (Smif8) respectively, and cultivated for 72 h.
Same infection conditions (MOI 103, 37 C) were chosen with a
trypsin activity of 20 U/mL. The previously used trypsin amount
based on cell concentration (105 U/cell) [23] was not applicable
for the MDCK.Xeno cells due to higher cell concentrations. Trypsin
concentrations over 50 U/mL led to cell lysis, visible by a fast
decrease in cell concentration with stable cell viability. With theltivated in shake flasks in Smif8 (A–C) and Xeno medium (D–F). Cell growth (A & D)
tion rates (C & F) were calculated for 24 h intervals until 96 h for glutamine ( ) and
(Gln), glutamate (Glu), ammonium (NH4+), glucose (Glc), lactate (Lac), VCC:
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first 24 h post infection (hpi), reaching 5.5  106 cells/mL and
11.5  106 cells/mL, followed by a fast drop in cell concentration
(Fig. 3). With the start of virus accumulation at 24 hpi, the average
cell diameter decreased by 3–4 mm until the end of the infection.
With MDCK.SUS2 cells a virus titer of 3.4 log10(HAU/100 mL)
(5  1010 virions/mL) was reached at 36 hpi (Fig. 3A) compared
to MDCK.Xeno, where virus production continued to increase to a
maximum titer of 3.6 log10(HAU/100 mL) (8  1010 virions/mL) at
48 hpi (Fig. 3B). Considering the higher cell concentration of
MDCK.Xeno cells, MDCK.SUS2 cells had a higher cell-specific virus
titer (9100 ± 700 virions/cell) compared to MDCK.Xeno cells
(7200 ± 400 virions/cell). In an attempt to further optimize infec-
tion conditions for MDCK.Xeno cells, different multiplicities of
infection (MOI), trypsin amounts and infection temperatures were
tested. However, all tested conditions had limited effect on the
final HA titer (data not shown) and therefore infection conditions
(MOI 103, 37 C) were chosen as before but with a slightly higher
trypsin activity of 30 U/mL. For a more detailed analysis of the
infection dynamics with MDCK.Xeno cells, three independent
infection experiments were performed (cultivation conditions as
described before). Additionally to the HA titer, the TCID50 titer
was evaluated. Similar to the previous experiments (Fig. 3) the
results showed a robust infection at the chosen conditions. In the
three independent experiments, very consistent cell concentra-
tions and HA titer (3.6 log10(HAU/100 mL)) were reached (Fig. 4).
High infectious virus titers exceeding 109 infectious virions/mL
(TCID50) were detected as soon as 24 hpi with a maximum at 30
hpi (2.7  109 infectious virions/mL). Afterwards, the infectiousFig. 3. Influenza A virus production of MDCK.Xeno and MDCK.SUS2 cells in batch cultur
flasks for 72 h and infected with influenza A virus. Cell diameter, viable cell concentratio
MOI: 103, 37 C, trypsin: 20 U/mL (2.5  106 (Xeno) & 5  106 (SUS2) U/cell);j viable
bars: SD of three parallel infections.
Fig. 4. Optimized influenza A virus production of MDCK.Xeno cells in batch culture. In thr
with influenza A virus. After infection, the cell concentration, viability and cell diameter (
U/mL (4  106 U/cell); j viable cell concentration, average cell diameter, viabi
experiments.virus titer declined and was finally reduced by three orders of mag-
nitude at 60 hpi (Fig. 4B). Both dynamics for infectious titer and
total number of virus particles (based on HA) were very repro-
ducible between the experiments, higher variations were observed
for cell concentration, viability and cell diameter during cell death
after virus production (>24 hpi) (Fig. 4A). For these independent
experiments, the mean CSVY was slightly higher (8200 ± 1100 viri-
ons/cell) compared to the previous experiment (Fig. 3), but with
higher variability due to variations of biological replicates. Previ-
ously reported CSVY for this cell line fell in the range between
7000–10,000 virions/cell [15,23] and correspond to our findings.
Even though higher virus titers have been reported already for
MDCK cell lines [26,48], an influenza virus A titer of 3.6 log10
(HAU/100 mL) was the highest titer we have reached with batch
or fed-batch experiments, so far.
3.4. Influenza A virus production with MDCK.Xeno cells in semi-
perfusion
In a next step, a semi-perfusion strategy was evaluated in shake
flasks to achieve even higher cell concentrations (>15  106 cells/
mL) and to investigate options regarding the establishment of
bioreactor processes in perfusion mode. In particular, we wanted
to verify that influenza virus production with MDCK.Xeno cells
was possible at high cell densities without a reduction in CSVY
(the so-called ‘‘high cell density effect”). In first attempts, the feed-
ing strategy was optimized towards the extension of the exponen-
tial cell growth phase with high specific growth rates. In
preliminary experiments a CSPR of 2.5 pL/(cell h) was determinede. MDCK.Xeno (A) and MDCK.SUS2 (B) cells were cultivated in three parallel shake
n (VCC) and virus titer (based on HA assay) were monitored for 72 h post infection.
cell concentration (VCC), average cell diameter, total virus titer (HA titer); Error
ee independent experiments, MDCK.Xeno cells were cultivated for 72 h and infected
VCC) (A) as well as HA and TCID50 (B) was monitored. MOI: 103, 37 C, trypsin: 30
lity, HA titer, infectious titer (TCID50); Error bars: SD of three independent
7008 T. Bissinger et al. / Vaccine 37 (2019) 7003–7010to allow high cell densites with MDCK.Xeno cells. Cell growth was
reduced in semi-perfusion compared to batch (msp < mmax), there-
fore a constant specific growth rate of 0.027 1/h was assumed.
Applying this feeding strategy, it was possible to reach cell concen-
trations of 40  106 cells/mL in 7 days (0.5  106 cells/mL seeding
cell concentration) (Fig. 5 B). Over the whole perfusion process,
4–5 times of the working volume (200–250 mL) of Xeno medium
was needed (Fig. 5A). By continued semi-perfusion even higher cell
concentration were possible (>60  106 cells/mL), but this was not
pursued due to process instability (lower specific growth rate, via-
bility) and handling issues. With higher cell concentrations, the
time interval between perfusion steps decreased, becoming limit-
ing at a certain time (Dt < 4 h). Variations of medium temperature,
pH and osmolality could potentially have created cell stress and
reduced the cell growth and viability. For these reasons, a cell den-
sity of 40  106 cells/mL was considered as optimal, to investigate
influenza A virus infection in high cell density conditions. Accord-
ingly, in another set of three experiments, MDCK.Xeno cells were
cultivated to 40  106 cells/mL and infected with influenza A virus
with a MOI of 103 (HCD1) and 101 (HCD2 and HCD3) (Fig. 5). The
higher MOI was chosen to limit cell growth post infection, and to
reduce the effect of perfusion (virus dilution) in the early infection
phase. Using low MOI infection conditions (MOI 103) (Fig. 5 black
circles), similar infection dynamics concerning maximum HA andFig. 5. Influenza A virus production with MDCK.Xeno cells in high cell density cult
40  106 cells/mL and evaluated for the production of influenza A virus. Accumulated viru
the fixed working volume (50 mL). A: total volume of Xeno medium used for perfus
accumulated virus titer of multiple harvests (HA); E: infectious virus titer (TCID50) in ce
HCD1 (MOI 103), HCD2 and HCD3 (MOI 101); 37 C, trypsin: 20 U/mL (5  107TCID50 titer were observed as for HCD2 and HCD3 performed at a
MOI of 101. Using the lower MOI, cells continued to grow post
infection to a maximum cell concentration of 60  106 cells/mL
and started to die with the onset of virus accumulation (24 hpi).
For higher MOI infections, virus release started earlier but cells
died rapidly after infection (<12 hpi), which resulted in fast virus
accumulation and lower maximum cell concentrations (Fig. 5B).
All infections showed very high virus titers (>4 log10(HAU/100 mL).
Considering the multiple harvests performed in each perfusion
step, the calculated accumulated titer exceeded 4.3 log10
(HAU/100 mL), reaching the maximum at 30 hpi (MOI 101) and
48 hpi (MOI 103), respectively. For the best performing experi-
ment (HCD 2), a HA titer of 4.2 log10(HAU/100 mL) was reached,
which corresponded to an accumulated titer of almost 4.5 log10
(HAU/100 mL). For the same cultivation, an accumulated titer of
1010 infectious virions/mL (TCID50) was obtained. Regarding HA
titers, these are the highest values reported for influenza A virus
production in animal cell culture, so far. Neither with other MDCK
cell-based processes [15,21,26,48] nor with other cell lines culti-
vated in high cell density culture [30,31], HA titers over 10,000
HAU (4 log10(HAU)) were achieved. Only the combination of high
cell density cultivation and high cell-specific productivity of
MDCK.Xeno cells allowed the improvement of virus titers by this
extent. The two infection experiments performed at a MOI ofure. MDCK.Xeno cells were cultivated in semi-perfusion shaker experiments to
s titers were determined from total virus titers produced in perfusion steps based on
ion; B: viable cell concentration (VCC); C: virus titer (HA) in cell suspension; D:
ll suspension; F: accumulated infectious virus titer of multiple harvests (TCID50) d
U/cell).
Table 1
Comparison of influenza A virus production with MDCK.Xeno cells in batch and semi-perfusion culture.
VCCmax Vmedium max. virus titer acc. virus titer tmax CSVY Vol. productivity Cell yield
HA TCID50 HA TCID50 (HA based) (HA based)
106 cells/mL mL log10(HAU/100 mL) 109 virions/mL log10(HAU/100 mL) 109 virions/mL h virions/cell 1012 virions/(L d) 106 cells/mL
Batch 9.3 75 3.60 2.2 3.60 2.2 140 8200 9.1 6.2
HCD 1 58.7 487 4.08 4.2 4.33 6.0 210 7300 5.0 6.0
HCD 2 45.6 448 4.19 7.5 4.49 9.4 193 13,600 8.6 5.1
HCD 3 41.5 373 4.16 4.2 4.35 4.3 177 10,800 8.2 5.6
HCD1-3 Cultivations of MDCK.Xeno in high cell density; HCD1: MOI 103, HCD2&3: MOI 101 (see Fig. 5).
VCC: viable cell concentration; Vmedium: overall volume of used cultivation medium; tmax: process time until maximum HA titer.
SCVY: cell-specific virus yield; volumetric productivity: total number of virions per day and Vmedium.
Cell yield: maximum number of cells per Vmedium.
T. Bissinger et al. / Vaccine 37 (2019) 7003–7010 7009101 not only showed the highest virus titers but also a better
overall performance compared to the low MOI infection. With this
strategy it was possible to improve CSVY, compared to conven-
tional batch experiments, to over 10,000 virions/cell (8000 viri-
ons/mL for batch). Additionally, the volumetric productivity of
these two experiments was similar to the batch experiment
(Table 1), proving this approach was not only valuable for increas-
ing virus titers but also commercially feasible with respect to med-
ium consumption. The lower productivity and cell-specific virus
titer for the low MOI infection (103) might be caused by feeding
issues (medium limitations) at cell concentrations of 60  106
cells/mL as already described earlier. Future experiments will focus
on scalable ‘‘real” perfusion systems using filtration retention
devices, where the virus can be retained in the cultivation broth,
and optimized feeding strategies can be applied both for cell
growth and virus production. Additionally, even higher cell con-
centration might be feasible using a continuous controlled perfu-
sion system [28,31,32].4. Conclusion
Optimization of MDCK cell-based influenza vaccine manufac-
turing has often focused on advanced reactor technology to
increase productivity. Only limited research, however, was dedi-
cated to medium development. Nevertheless, Huang et al., intro-
duced a new cell culture medium for the cultivation of MDCK
suspension cells, which enabled very promising influenza virus
titers [26]. In a long process (>180 days), we adapted our MDCK.
SUS2 cell line to the Xeno medium to generate the MDCK.Xeno cell
line, growing in single cell suspension. This newly established cell
line grew faster and to higher cell concentration than other MDCK
suspension cells [20–23,26,44], and showed various changes in
metabolism as well as in morphology compared to the original cell
line. Due to an improvement in cell concentrations, a higher virus
titer (3.6 log10(HAU/100 mL) was achieved in batch infections with
influenza A virus, compared to MDCK.SUS2 cells. For process inten-
sification, semi-perfusion enabled us to cultivate and infect this
MDCK.Xeno cell line in a high cell density environment. Here, we
were able to show cell concentrations up to 6  107 cells/mL,
producing an influenza A virus titer of up 4.2 log10(HAU/100 mL).
Both cell concentration (for MDCK.Xeno) and influenza A virus titer
are the highest reported for conventional MDCK cultivations
[15,26,31] and intensified processes [30,31,48]. A short process
time in semi-perfusion (<8 days), led to a process with similar
productivity compared to batch culture, despite high medium con-
sumption (5–7  volume of batch cultivations). Further optimiza-
tion of perfusion strategy should allow an even more efficient
utilization of perfusion medium and a further increase in process
productivity for both cells and viruses [29–32,49]. In particular,
with use of capacitance sensors for on line measurement of cell
concentrations and feeding control the implementation of highlyproductive continuous perfusion cultures should be feasible. With
the virus yields achieved, so far, very competitive cell culture-
based influenza vaccine manufacturing processes can be imple-
mented that help to overcome limitations of egg-based production
systems and contribute significantly to reduce time for pandemic
preparedness in case of an influenza epidemic.Acknowledgements
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